Certara celebrates its 200 published papers and 11 scientists on Stanford/Elsevier top 2% cited researchers list in 2025RADNOR, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its continued influence in pharmaceutical research. With more than 200 papers authored by Certara scientists* this past year and 11 Certara scientists included on the 2025 update of Stanford/Elsevier’s ranking of the top 2% most cited scientists a ...

Gold Equivalent Ounce ("GEO") Production of 13,868 GEO for the 3rdQuarter 2025Expanded crushing capacity results in substantial additional tonnage to the leach pad and record quarterly productionUnderground Development to access production stopes in Q4 supporting increase in mill head grade and production Underground Development delayed by 60 days due to additional portal support and shotcrete requirements 2025 Production Guidance revised to 50,000 to 55,000 GEOExploration Program expanded with an additiona ...

Chris Lau is an individual investor and economist with 30 years of experience covering life science, technology, and dividend-growth income stocks. He has degrees in Microbiology and Economics. Chris runs the investing group DIY Value Investing where he shares his top stock picks of undervalued stocks with catalysts for upside, dividend-income recommendations with quant and payment calendar tracking, high upside plays, and research requests to help you become a better do-it-yourself investor. Flagship Produ ...

Chris Lau is an individual investor and economist with 30 years of experience covering life science, technology, and dividend-growth income stocks. He has degrees in Microbiology and Economics. Chris runs the investing group DIY Value Investing where he shares his top stock picks of undervalued stocks with catalysts for upside, dividend-income recommendations with quant and payment calendar tracking, high upside plays, and research requests to help you become a better do-it-yourself investor. Flagship Produ ...

Core Viewpoint - Cerrado Gold Inc. announces the resignation of Mr. Robert Campbell from its board of directors as he intends to retire, with management expressing gratitude for his contributions and wishing him well in retirement [1] Group 1: Company Overview - Cerrado Gold is a Toronto-based gold production, development, and exploration company, fully owning the Minera Don Nicolás and Las Calandrias mines in Argentina [2] - The company holds an 80% interest in the Lagoa Salgada VMS project in Portugal and is developing the Mont Sorcier Iron project in Canada, which it fully owns [2] Group 2: Operations in Argentina - In Argentina, Cerrado is enhancing asset value at the Minera Don Nicolás operation through operational optimization and increasing production at the Las Calandrias heap leach project [3] - An extensive exploration campaign is ongoing to unlock potential resources in the Deseado Masiff region [3] Group 3: Operations in Portugal - In Portugal, Cerrado is focused on the Lagoa Salgada VMS project, which is located on the Iberian Pyrite Belt and is characterized by high-grade polymetallic mineralization including zinc, copper, lead, tin, silver, and gold [4] - The project has significant exploration potential across its 7,209-hectare property and is strategically located 80 km from Lisbon, benefiting from excellent infrastructure [4] Group 4: Operations in Canada - Cerrado's Mont Sorcier Iron project has the potential to produce premium iron concentrate with low operating costs and a long mine life [5] - The high-grade and high-purity product supports the transition of steel producers to electric arc furnaces, aiding in the decarbonization of the industry [5]

RADNOR, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2025 after the market close on Thursday, November 6th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived w ...

Adding three new drill rigs to accelerate and expand the exploration program following positive initial findingsExploration budget to be increased materiallyMDN will certify its on-site Laboratory for immediate turn around of assay results TORONTO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Cerrado Gold Inc. [TSX.V:CERT][OTCQX:CRDOF; FRA:BAI0] (“Cerrado” or the “Company”) announces that the Company has revised its exploration plans to accelerate the previously announced 20,000 metres exploration program at its Mine ...

Core Insights - The overall end market environment is subdued, but the company is focused on accelerating growth despite these conditions [1] - The company has made significant investments in sales and marketing over the past couple of years to build out its commercial organization [1] - The next phase of investment includes research and development (R&D), which is expected to continue into the next year [1] - Accelerated growth has been observed from the build-out of the commercial organization, particularly reflected in results from Tier 3 customers this year [1]

Core Insights - The overall end market environment is subdued, but the company is focused on accelerating growth despite these challenges [1] - The company has made significant investments in sales and marketing over the past couple of years to build out its commercial organization [1] - The next phase of investment includes research and development (R&D), which is expected to continue into the next year [1] - Accelerated growth has been observed from the build-out of the commercial organization, particularly reflected in results from Tier 3 customers [1]

Summary of Certara FY Conference Call - September 10, 2025 Company Overview - **Company**: Certara (NasdaqGS:CERT) - **Industry**: Health Technology and Biosimulation Key Points and Arguments Growth Strategy - Certara is focused on accelerating organic growth despite a subdued market environment, targeting mid-single-digit growth rates [4][5] - Investments in sales, marketing, and R&D are being made to enhance the commercial organization and software platforms [4][5] - New software enhancements, including Certara IQ (AI-enabled software for Quantitative Systems Pharmacology, QSP), are expected to drive growth [5][10] R&D and Product Development - Certara is addressing critical pain points in drug development, particularly the high failure rates of drug trials, by enhancing software capabilities [7] - The company has launched Certara Cloud, which has seen rapid adoption, particularly among large biopharma customers [11][12] - The tiered customer structure includes: - **Tier 1**: Large biopharma (50% of revenue) - **Tier 2**: Mid-sized companies (20% of revenue) - **Tier 3**: Biotechs (30% of revenue) [14][15] Market Dynamics - The funding environment for tier three customers remains challenging, but Certara has successfully targeted biotechs with funding potential [13][15] - The FDA's directive to shift away from animal testing is seen as a tailwind for Certara, enhancing customer discussions and driving demand for SIMCYP and QSP [24][34] Financial Performance - Certara expects an adjusted EBITDA margin of 30-32% for the year, consistent with previous performance [20] - The company is on track to meet its full-year plan despite some timing issues in software bookings for tier one customers [16][17] AI and Technology Integration - The acquisition of Vyasa has enabled Certara to integrate AI technology into its workflow and product offerings [25][26] - The co-author tool for regulatory writing has demonstrated a 40% efficiency improvement, appealing to regulatory customers [27] M&A and Strategic Review - Certara is actively engaged in a strategic review of its regulatory business, which has returned to growth with a 20-30% adjusted EBITDA margin [43][44] - The company is focused on software acquisitions to shift its revenue mix from services to software, aiming for a balanced profitability profile [45][46] Capital Allocation - Certara prioritizes R&D investments while also considering M&A opportunities and share buybacks, having authorized a $100 million share repurchase program [47][48] Additional Important Insights - Certara's longstanding relationship with the FDA provides a competitive advantage, as many FDA users are familiar with Certara's software [32][33] - The company is well-positioned to help biopharma clients find efficiencies across the drug development cycle, from discovery to submission [30][31] - The integration of Camaxon, a chem-informatics software company, is progressing well, with expectations to enhance margins and product offerings [40][41]